{'fraction_non_alphanumeric': 0.03214285714285714, 'fraction_numerical': 0.007142857142857143, 'mean_word_length': 5.678571428571429, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Thrombosis in the antiphospholipid syndrome.

Antiphospholipid antibodies (aPLA) are heterogenous antibodies directed against phospholipid–protein complexes. Antiphospholipid syndrome (APS) is diagnosed when arterial and/or venous thrombosis or recurrent fetal loss occurs in a patient in whom screening for aPLA are positive. Because both thrombosis and fetal loss are common in the population, persistent positivity of aPLA is important. This syndrome is predominant in females (female to male ratio is 5 to 1), especially during the childbearing years[1-7].